Apple Turns 50: From Garage Startup to AI Crossroads 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
LOS ANGELES, July 11, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (Nasdaq:SVA) for possible violations of federal securities laws between April 30, 2013 and May 16, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired Sinovac shares during the Class Period should contact the firm prior to the September 1, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Sinovac made false and/or misleading statements and/or failed to disclose: that Chairman and CEO Weidong Yin bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; that such conduct would subject the Company to heightened regulatory scrutiny; and that as a result of the above, Sinovac’s public statements were materially false and misleading at all relevant times. Upon release of this news, shares of Sinovac fell in value materially, which caused investors harm.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethics rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
